New hope for hard-to-treat colorectal cancer: triple therapy enters phase 2 trial
NCT ID NCT06589440
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This study tests a new oral drug (SR-8541A) combined with two immunotherapy drugs for people with a tough-to-treat type of colorectal cancer (MSS-CRC) that has spread and stopped responding to standard treatments. The goal is to find the best dose and see if the combination is safe and shrinks tumors. About 70 adults with or without liver metastases will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY METASTATIC MICROSATELLITE STABLE COLORECTAL CANCER (MSS-CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlantic Health
RECRUITINGMorristown, New Jersey, 07960, United States
-
Swedish
RECRUITINGSeattle, Washington, 98104, United States
-
Texas Oncology- Austin
RECRUITINGAustin, Texas, 78745, United States
-
Texas Oncology- Northeast Texas
RECRUITINGTyler, Texas, 75702, United States
-
Texas Oncology- Sammons- DFW
RECRUITINGDallas, Texas, 75246, United States
-
The University of Texas M.D. Anderson Cancer Center GI Medical Oncology Dept
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••